# Effect of Velphoro on Serum Phosphate and Albumin in Peritoneal Dialysis Patients

> **NCT04046263** · PHASE4 · COMPLETED · sponsor: **University of Colorado, Denver** · enrollment: 17 (actual)

## Conditions studied

- Peritoneal Dialysis Complication
- Hyperphosphatemia
- Hypoalbuminemia

## Interventions

- **DRUG:** Sucroferric Oxyhydroxide Chewable Tablet

## Key facts

- **NCT ID:** NCT04046263
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-01
- **Primary completion:** 2021-07-31
- **Final completion:** 2021-07-31
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2022-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04046263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04046263, "Effect of Velphoro on Serum Phosphate and Albumin in Peritoneal Dialysis Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04046263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*